arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

NewAmsterdam Pharma Co N.V.

NAMS

$27.96 ▲ +0.35 (+1.25%) at close

16 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

NewAmsterdam Pharma Co N.V. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4B

Dividend Yield —

Revenue Growth 2.1% ↗

Op. Margin None

ROIC -6.9% ↗

FCF / Share $-0.25

Trailing P/E —

Price / Book 4.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.04M

↑ +2.1% —

Net Income Profit after all expenses

$-48.44M

↓ -22.6% —

Operating Margin Operating profit as % of sales

-186.1%

↑ +45.0% —

FCF / Share Free cash flow per share

$-0.25

↑ +19.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	2.1% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-74%)	-99.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1347%)	-98.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1335%)	740.1% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+9151%)	112.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1307%)	1490.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+18532%)	889.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+11023%)	32.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+309%)	-83.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1147%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	-17.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	33.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-238.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	63.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	67.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-58.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	68.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	12.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-107.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-22.6% Weak ↑ Weak Improving Year-over-year change in net income	18.7% Good ↑ Good Improving Year-over-year change in net income	-332.5% Weak ↓ Weak Declining Year-over-year change in net income	55.5% Excellent ↑ Excellent Improving Year-over-year change in net income	57.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-86.2% Weak ↓ Weak Declining Year-over-year change in net income	64.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-1.9% Weak Weak Year-over-year change in net income	-123.2% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	19.9% Good ↑ Good Improving Year-over-year change in free cash flow	—	-108.7% Weak ↓ Weak Declining Year-over-year change in free cash flow	44.2% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	49.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	—	76.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-59.6% Weak Weak Year-over-year change in free cash flow	-58.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	-29.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	—	—	—	-186.1% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1341%)	—	-338.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2356%)	-85.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-673%)	—	—	—	—	—	-461.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3179%)	—	—	—
Effective Tax Rate (%) (%)	—	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	—	—	-90.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-856%)	—	—	-57.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-577%)	—	—	—	—	—	-486.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4158%)	—	—	—
FCF Margin (%) (%)	—	—	—	-196.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	—	-293.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-42.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	-369.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.63x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.55x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.46x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	2.17x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.38x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-6.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-3.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-14.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-7.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-8.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-5.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-11.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-7.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	-11.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-173%)	-9.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	-2.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-115%)	-5.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-134%)	-12.2% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-181%)	-4.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-10.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-167%)	-22.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-252%)	-17.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	-14.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-195%)	-10.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-168%)	-10.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-457.61M	$-490.00M	$-538.41M	$-563.86M	$-748.42M	$-771.74M	$-422.73M	—	—	$-340.45M	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.02	—	$0.00	$0.16	$0.03	—	$0.31	$0.02	$0.02	—	$0.04	$0.02	$0.11	—	—	—
Basic EPS, GAAP (USD)	$-0.40	$-0.63	$-0.61	$-0.15	$-0.34	$-0.95	$-0.18	$-0.41	$-1.06	$-0.60	$-0.57	$-0.47	$-0.51	—	—	—
Free Cash Flow per Share (USD)	$-0.25	—	$-0.28	$-0.32	$-0.31	—	$-0.13	$-0.57	$-0.62	—	$-0.57	$-0.36	$-0.39	—	—	—
Book Value per Share (USD)	$5.70	$5.97	$6.43	$6.92	$6.93	$7.01	$4.00	$4.09	$4.59	—	$4.02	$4.55	$4.88	$11.86	—	—
Tangible Book Value per Share (USD)	$5.70	$5.97	$6.43	$6.92	$6.93	$7.01	$4.00	$4.09	$4.59	—	$4.02	$4.55	$4.88	$11.86	—	—
Basic Weighted Avg Shares (shares)	121.72M	—	119.00M	118.56M	116.12M	—	94.75M	94.71M	88.38M	—	82.47M	82.06M	81.63M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$590.62M	$589.91M	$674.06M	$733.34M	$776.39M	$756.50M	—	—	$428.10M	—	—	—	—	$441.92M	—	—
Total Equity (USD)	$665.22M	$683.43M	$728.07M	$778.50M	$777.36M	$757.50M	$378.86M	$387.44M	$411.80M	$288.39M	$331.83M	$373.34M	$398.41M	$430.07M	$-113.82M	$-73.03M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$3.04M	$32.00K	$348.00K	$19.14M	$2.98M	$12.77M	$29.11M	$2.28M	$1.40M	$803.00K	$2.94M	$1.72M	$8.63M	—	—	—
Depreciation Expense (USD)	$62.00K	$59.00K	$64.00K	$45.00K	$52.00K	$51.00K	$28.00K	$19.00K	$15.00K	$13.00K	$14.00K	$13.00K	$9.00K	—	—	—
Net Income, GAAP (USD)	$-48.44M	$-74.92M	$-72.00M	$-17.36M	$-39.53M	$-92.18M	$-16.65M	$-39.01M	$-93.77M	$-49.49M	$-47.13M	$-38.29M	$-42.02M	—	—	—
Operating Cash Flow (USD)	$-30.60M	$-40.88M	$-32.77M	$-37.67M	$-36.47M	$-37.48M	$-12.50M	$-53.98M	$-54.60M	$-33.07M	$-46.98M	$-29.30M	$-31.86M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 16 quarters

NewAmsterdam Pharma Co N.V.

Analytical Summary

16-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NAMS with peers